Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis - Wikidata - awgldk - TriplyDB

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

http://www.wikidata.org/entity/Q36377090

about

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations Tuberculosis therapy for 2016 and beyond.Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy.Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide.Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection.Physiology, Biochemistry, and Applications of F420- and Fo-Dependent Redox Reactions.Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions.Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.The safety and tolerability of the second-line injectable antituberculosis drugs in children.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives.Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis.Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds.News on therapeutic management of MDR-tuberculosis: a literature review.Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?Real-Time Sequencing of Mycobacterium tuberculosis: Are We There Yet?Design, Synthesis and Characterization of N-oxide-containing Heterocycles with In vivo Sterilizing Antitubercular Activity.Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.Synergistic Response of Rifampicin with Hydroperoxides on Mycobacterium: A Mechanistic Study.Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance.Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis.Evolution of Phenotypic and Molecular Drug Susceptibility Testing.Strain Diversity and the Evolution of Antibiotic Resistance.Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management.Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.Bedaquiline resistance: Its emergence, mechanism and prevention.Genomic Epidemiology of Tuberculosis.The Nature and Evolution of Genomic Diversity in the Mycobacterium tuberculosis Complex.Editorial: Reassessing Twenty Years of Vaccine Development against Tuberculosis.Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery.Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.Expanding benzoxazole based inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitor structure-activity as potential anti-tuberculosis agents.A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.

P2860

Q28072205-EB1E668D-570B-4876-B7AB-1A50966210CF Q30248788-355042CD-4E6E-4BCF-B363-FA6D8376768A Q30249515-F8E6A631-ACBA-4AF5-B257-FC0629B0957A Q33576860-7C247523-9A6B-4557-AC7E-D3C20AFA8616 Q33589758-93541069-3BEF-4D38-A7EA-1C89054D281C Q33599760-8C4A4AB4-6B03-4A7F-90BB-11C927F5EE31 Q33913678-4F276429-9A35-4E75-AA4C-CD18A465FEC7 Q36902459-9502AF12-1DD3-49B5-85E3-C03A0789CE19 Q37089655-F0C54829-C175-4E8B-9D60-7A1A3F6F324A Q37203747-B0DAD2B3-6A83-4E09-A4DC-9B7021A166F1 Q38672958-3C7B8A5E-749E-45F5-85C4-4396870C32A7 Q38912109-F4827D6E-CF73-4A59-8371-7C1381F3E702 Q38933875-9EC028F3-1FEB-4DE0-83B0-2231B9B3087A Q38995175-E8785E1A-34B6-42CD-9C8C-4A6D9A98E93A Q39038482-39B5AD5C-4D37-46EE-84D1-B09BB5042F50 Q39104640-102B9E68-951B-43C4-A1C4-6E408A12F77A Q39354581-FF40645A-AFAB-456C-B0B6-6FEE6CBBC4F2 Q39398924-0144F3B3-A02F-4145-85F3-C42A5452EBA0 Q40065397-C9DAA4EB-0B13-47F5-B8A4-D41CDFA6FDCE Q40076101-5724CC7F-CC7E-4830-A9D9-191F3510046D Q40290488-2CFD1B1F-75F2-499B-B42C-E2A6480519DF Q41992338-176D67D8-A3F5-4398-A269-B90C784A87A5 Q45198957-2814D95C-525C-4749-B342-8DF3BC0E1035 Q46256666-F685C6C4-3842-44D8-8EBD-F52EFBC6C565 Q46427262-21AF3E4B-1CF8-4382-9F96-F3AC6580F8E9 Q47446710-E5D11ECC-F99C-4A50-A931-21AA0494E6E0 Q47564881-0EF12192-6E59-499C-B023-2570D013F709 Q47632774-CDE7ECF4-73A7-4A4C-8688-5E5E1339BE9C Q47851713-32254997-1B43-493E-AF21-B5A8D029C423 Q48262048-D7D8CB1F-9423-431B-A4A6-6803AE14B9A0 Q50033600-1023EB4F-2E0E-4BCA-A3D2-B2A97B033B6D Q50068179-6E0ABDE9-D436-4DEF-8D6D-1AC9377D1849 Q50107990-72C7D1B4-62E7-47B9-BCB6-CDD1FDC8733D Q50108000-4C568DE7-B7AB-4B7E-8BE0-926A5E4D4471 Q50321322-120765F0-360F-4DD1-A4FD-F320093828B5 Q52324625-6347330C-34A1-433C-8060-FDDDA3ACC063 Q52688603-FA6DE6CA-72D2-4C5F-80C5-1839502D9921 Q52707803-97BE7A1E-E597-4788-9BB1-9864996488BC Q53684814-60BD43D7-F6C5-4701-8AE4-A694838907C7 Q53689031-5F7956FB-AC0F-4AF5-9C30-44C06B545394

P2860

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

http://www.wikidata.org/entity/Q36377090

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

@ast

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

@en

type

label

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

@ast

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

@en

prefLabel

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

@ast

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

@en

P1433

Q36377090-620781BD-F2A8-4A9C-A610-E839E80E4A80

P1476

Q36377090-CF0996EF-76D9-4632-9093-EEECCE81E41E

P2093

Q36377090-0DA1D6CF-823E-4AAE-86AA-22DFAC9CE3EF

Q36377090-20778942-9E44-4F26-86D4-18E4EE31BFD0

Q36377090-5D049760-3321-46AE-9C1B-22D8D21224B2

Q36377090-79DBC060-F458-468E-9D01-C669C60326D3

Q36377090-8CA1A359-B33F-44CD-9313-6BFA407905FC

Q36377090-8D91B39E-CF4E-4DE5-8013-B74ED1F56FC4

Q36377090-B26B4965-29D1-43B7-A90A-B8EDBECF9B76

Q36377090-CE413AB1-E20F-488B-BEB5-E266B7D6A61A

Q36377090-F1012814-927E-497E-853F-6811A60F2EFD

Q36377090-FBE8CA0C-5B21-4416-9911-889E81151A52

P2860

Q36377090-2501A48A-D653-4AD1-A4E9-F0D4746E8E26

Q36377090-871B42E3-5BF8-408A-A2B0-0BA49AFD4662

Q36377090-8FC2C943-2218-4655-8E0E-601E884CF098

Q36377090-B62E8FC9-C558-4E1B-8805-BC23CCFF9BC3

P304

Q36377090-FE456265-89D0-4250-B3D2-E93083F10FE3

P31

Q36377090-D57A712E-1BB5-4527-913E-FD1DAD7A2B3A

P356

Q36377090-B9B594BD-3221-4C9E-8F45-C97314BC5A64

P407

Q36377090-63205876-1024-4049-80A6-976F052F5963

P433

Q36377090-099925F4-29AF-43CE-B567-BF4660F227AD

P478

Q36377090-238940E1-F25A-48C7-84C6-A942FA7A7F45

P50

Q36377090-073A1F25-7A6A-4F95-A62C-C484318790D5

Q36377090-3C1A3F4F-FBC3-4253-9ED1-B53F42AB4982

Q36377090-AEE0C80C-F65A-437F-AD1E-CEA00EA863B0

Q36377090-C17F8BCF-D9A1-408F-9C01-30A0E612DA1B

P577

Q36377090-95B53307-7750-44D3-8EFE-9FEB62B1C736

P698

Q36377090-6FDAF6BD-2DAA-42EB-B5CF-789E56286305

P921

Q36377090-FB0C7040-DB64-42E2-A78D-693301B42917

P932

Q36377090-4E5A8D98-32C7-40EE-9F1F-5C6DFAB85F3E

P356

P1433

The New England Journal of Medicine

P1476

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

@en

P2093

Bettina Schulthess

http://www.w3.org/2001/XMLSchema#string

Claudia Ritter

http://www.w3.org/2001/XMLSchema#string

Erik C Böttger

http://www.w3.org/2001/XMLSchema#string

Guido V Bloemberg

http://www.w3.org/2001/XMLSchema#string

Julia Feldmann

http://www.w3.org/2001/XMLSchema#string

Peter M Keller

http://www.w3.org/2001/XMLSchema#string

Rico Hömke

http://www.w3.org/2001/XMLSchema#string

Sebastien Gagneux

http://www.w3.org/2001/XMLSchema#string

Sonia Borrell

http://www.w3.org/2001/XMLSchema#string

Thomas Rothe

http://www.w3.org/2001/XMLSchema#string

P2860

Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.

Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes.

Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients.

Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis

P304

1986-1988

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMC1505196

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Mireia Coscolla

Tsogyal D Latshang

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26559594

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

4681277

http://www.w3.org/2001/XMLSchema#string